E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
HER-2 overexpressing primary operable breast cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006187 |
E.1.2 | Term | Breast cancer |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the added efficacy obtained by the association of Trastuzumab with RAD001 as preoperative therapy of primary HER-2 positive breast cancer as shown by increased clinical tumor response rate. |
|
E.2.2 | Secondary objectives of the trial |
- To compare the inhibition of the two pathways: RAS/RAF/MAPKinase and PI3Kinase/AKT/mTor. - To evaluate the pre-treatment molecular characteristics of tumor and serum or their modifications early in the treatment as being predictive of clinical response. - To compare the frequency of pathological complete response achieved in the two groups after 6 weeks of treatment. - To assess the disease-free survival at 3 years. - To evaluate safety and tolerability of the two treatment regimens. - To analyse the possible relationships between treatment toxicity and constitutional gene polymorphisms linked to the administered agents. - To analyse the possible relationships between response and molecular pharmacodynamic assessments: proteomics (blood samples), Bioplex protein array (tumor) and IHC (tumor). - To analyse the drug levels and pharmacokinetic assessments of the association RAD001 and trastuzumab. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
- Biological study - Molecular diagnosis and signal pathay functioning - Pharmacogenetic - Pharmacokinetic - Apoptosis induction - Proteomic |
|
E.3 | Principal inclusion criteria |
1) Adult female patients (≥ 18 years old), 2) Histologically-confirmed diagnosis of invasive breast cancer, previously untreated (patients who have been treated for cancer of the controlateral breast cancer can be included if there is at least a 2 year time interval from last systemic treatment for breast cancer before randomization into this study), 3) Candidate for breast-conserving surgery; clinical stage: cT1-3, cN0-2 4) HER-2 positive primary tumor, defined as: IHC 3+, or IHC 2+ and FISH positive (centralized confirmation), 5) Clinical stage M0 (bone scan, chest X-ray, liver ultrasound required at screening to exclude metastatic disease), 6) WHO performance status ≤ 1 7) Adequate bone marrow function (WBC ≥ 3.5 x109/L; ANC ≥ 1.5 x109/L; Platelets ≥ 100 000x109/L; Hb ≥10 g/dL), 8) Adequate liver function (serum bilirubin ≤ 1.5 ULN, serum transaminases activity ≤ 2.5 ULN; alkaline phosphatase ≤ 2.5 ULN), 9) Adequate renal function (creatinine ≤ 1.5 mg/dL or creatine clearance ≥ 60 mL/min), 10) Adequate cardiac (MUGA scan or echocardiography, FEV > 55%) and pulmonary functions, 11) Potentially reproductive patients must agree to use an effective contraceptive method while on treatment 12) Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrollment and/or urine pregnancy test 48 hours prior to the administration of the first study treatment, 13) Patients must be affiliated to a Social Security System, 14) Patient information and written informed consent form signed. |
|
E.4 | Principal exclusion criteria |
1) Patient not candidate for breast conserving surgery or patient candidate to neoadjuvant chemotherapy, 2) Patients with inflammatory breast cancer or patient with bilateral breast cancer, 3) Patients receiving concomitant anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy and radiotherapy, 4) Known hypersensitivity to everolimus or sirolimus, to trastuzumab or lactulose, 5) ≥ gr 3 hypercholesterolemia/hypertriglyceridemia or ≥ gr 2 hypercholesterolemia/hypertriglyceridemia with history of coronary artery disease (despite lipid-lowering treatment if given), 6) Patient with uncontrolled infection, 7) Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, cardiac disease, uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within one year, chronic liver or renal disease, active GI tract ulceration, severly impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on room air), 8) Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itroconazole, Voriconazole, Ritonavir, Telithromycin) within the last 5 days prior to randomization, 9) Patients with a known history of HIV seropositivity, 10) Pregnant women, women who are likely to become pregnant or are breast-feeding, 11) Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial, 12) Patients who received any other investigational drugs within the 30 days prior to the screening visit, 13) Patients unwilling to participate to the biological investigations, 14) Individual deprived of liberty or placed under the authority of a tutor. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the added efficacy obtained by the association of Trastuzumab with RAD 001 as preoperative therapy of primary HER-2 positive breast cancer as shown by increased clinical tumor response rate (WHO criteria). Clinical response will be measured by echography within 1 week prior to surgery. WHO criteria will be used without confirmation. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
proteomic, molecular diagnosis and signal pathway functioning, apoptosis induction |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Trastuzumab vs trastuzumab + RAD 001 |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Trastuzumab vs trastuzumab + RAD 001 |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |